|
Traditionally, the activity of cannabinoid (CB) agonists was thought to be transduced by a pair of G protein-coupled receptors, CB1 and CB2.1 CAY10429 (abnormal cannabidiol) is a synthetic regioisomer of cannabidiol that fails to elicit either CB1 or CB2 responsiveness and is without psychotropic activity. CAY10429 induces endothelium-dependent vasodilation via a CB1/CB2/NO-independent mechanism.2 At a dose of 20 µg/g in rats, CAY10429 showed hypotensive activity that could not be antagonized by cannabidiol or SR141716A. CAY10429 is therefore believed to activate a third type of CB receptor, provisionally called the non-CB1/CB2 endocannabinoid receptor. CAY10429 also acts via these receptors to regulate the migratory activity of murine BV-2 microglial cells, with an EC50 of 600 nM.3
|
|
1
Felder, C.C., Joyce, K.E., Briley, E.M., et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48 443-450 (1995).
2
Járai, Z., Wagner, J.A., Varga, K., et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 96(24) 14136-14141 (1999).
3
Walter, L., Franklin, A., Witting, A., et al. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23(4) 1398-1405 (2003).
|